KRAS mutational analysis for colorectal cancer

PLoS Currents

Volumn , Issue SEP, 2010, Pages

  Wang, Grace ^a   Kelley, Robin K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053539583     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1175     Document Type: Article

References (43)

1. Normanno, N., et al., Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol, 2009. 6(9): p. 519-27.
2. KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer. Technol Eval Cent Asses Program Exec Summ, 2009. 23(6): p. 1-3.
3. National Cancer Institute. SEER Stat Fact Sheets: Colon and Rectum. 2010 [cited 2010 April 26];
4. NCCN Updates Guidelines for Colorectal Cancer; NCCN announces new updates to the NCCN Guidelines for Colon and Rectal Cancers. The updates include recommendations to the pre-treatment work-up and use of anticancer agents in patients with metastatic colorectal cancer depending on the status of the tumor's KRAS gene. The changes are based on recent studies demonstrating that the tumor KRAS gene status is highly predictive of outcome with certain therapies, in Business Wire. 2008.
5. National Comprehensive Cancer Network. Colon Cancer. NCCN Clinical Practice Guidelines in Oncology 2009 [cited 2009 October 21];
6. Allegra, C.J., et al., American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol, 2009. 27(12): p. 2091-6
7. Oliner, K., et al., A comparability study of 5 commercial KRAS tests. Diagn Pathol. 5(1): p. 23
8. Benvenuti, S., et al., Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res, 2007. 67(6): p. 2643-8.
9. Bibeau, F., et al., Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol, 2009. 27(7): p. 1122-9.
10. Cappuzzo, F., et al., Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer, 2008. 99(1): p. 83-9.
11. De Roock, W., et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol, 2008. 19(3): p. 508-15.
12. Di Fiore, F., et al., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer, 2007. 96(8): p. 1166-9.
13. Di Nicolantonio, F., et al., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008. 26(35): p. 5705-12.
14. Frattini, M., et al., PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer, 2007. 97(8): p. 1139-45.
15. Freeman, D.J., et al., Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer, 2008. 7(3): p. 184-90.
16. Garm Spindler, K.L., et al., The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol, 2009. 20(5): p. 879-84.
17. Goncalves, A., et al., A polymorphism of EGFR extracellular domain is associated with progression freesurvival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer, 2008. 8: p. 169.
18. Khambata-Ford, S., et al., Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol, 2007. 25(22): p. 3230-7.
19. Laurent-Puig, P., et al., Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol, 2009. 27(35): p. 5924-30.
20. Lievre, A., et al., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008. 26(3): p. 374-9.
21. Lievre, A., et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 2006. 66(8): p. 3992-5.
22. Loupakis, F., et al., PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol, 2009. 27(16): p. 2622-9.
23. Loupakis, F., et al., KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer, 2009. 101(4): p. 715-21.
24. Lurje, G., et al., Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with singleagent cetuximab. Clin Cancer Res, 2008. 14(23): p. 7884-95.
25. Molinari, F., et al., Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer, 2009. 100(7): p. 1087-94.
26. Moroni, M., et al., Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol, 2005. 6(5): p. 279-86.
27. Oden-Gangloff, A., et al., TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer, 2009. 100(8): p. 1330-5.
28. Perrone, F., et al., PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol, 2009. 20(1): p. 84-90.
29. Personeni, N., et al., Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res, 2008. 14(18): p. 5869-76.
30. Prenen, H., et al., PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res, 2009. 15(9): p. 3184-8.
31. Sartore-Bianchi, A., et al., PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res, 2009. 69(5): p. 1851-7.
32. Sohn, B.S., et al., The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Oncology, 2009. 77(3-4): p. 224-30.
33. Souglakos, J., et al., Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer, 2009. 101(3): p. 465-72.
34. Yen, L.C., et al., Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg. 251(2): p. 254-60.
35. Amado, R.G., et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008. 26(10): p. 1626-34.
36. Bokemeyer, C., et al., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2009. 27(5): p. 663-71.
37. Hecht, J.R., et al., A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol, 2009. 27(5): p. 672-80.
38. Karapetis, C.S., et al., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008. 359(17): p. 1757-65.
39. Tol, J., et al., Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med, 2009. 360(6): p. 563-72.
40. Van Cutsem, E., et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009. 360(14): p. 1408-17
41. Linardou, H., et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol, 2008. 9(10): p. 962-72
42. Qiu, L.X. et al., Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies. Eur J Cancer, 2010. (in press). doi:10.1016/j.ejca.2010.05.022
43. Yen, L.C., et al., Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg, 2010. 251(2): p. 254-60